FGF23 and phosphaturic mesenchymal tumor: First described by McCance [2] and Prader [3], TIO has been associated with increased production of the phosphaturic hormone Fibroblast Growth Factor 23 (FGF23), usually by mesenchymal tumors of soft tissue or bone known as “Phosphaturic Mesenchymal Tumors” (PMTs) [4].